Post-Transplant KRd Maintenance May Allow for Superior Outcomes in Newly Diagnosed Multiple MyelomaFebruary 3rd 2023
Andrzej Jakubowiak, MD, PhD, highlighted several key studies that influenced the development and design of the ATLAS trial, introduced conclusions from the initial efficacy data, and discussed how ongoing analysis could further contextualize and inform post-transplant treatment approaches in multiple myeloma.
MRI-Guided SBRT Could Represent Safer, More Precise Radiotherapy Option for Prostate CancerFebruary 2nd 2023
Amar U. Kishan, MD, discusses the safety results of MRI-guided SBRT compared with the current standard of care, highlights the benefits of using an MRI to guide radiation for patients with prostate cancer, and explains other areas where MRI-guided SBRT could explored.
Jakubowiak Highlights PFS Benefit Seen With KRd Maintenance in Newly Diagnosed Multiple MyelomaMarch 2nd 2023
Dr Jakubowiak discusses interim findings from the ATLAS trial of lenalidomide plus carfilzomib and dexamethasone vs lenalidomide maintenance in patients with newly diagnosed multiple myeloma, contextualizes these data within the broader post-transplant landscape, and previews the next steps for this research.